Posted by Michael Wonder on 15 May 2024
PTC Therapeutics announces FDA acceptance and priority review of the BLA for Upstaza
14 May 2024 - PDUFA target action date of 13 November 2024.
PTC Therapeutics announced today that the FDA has accepted for filing the biologics license application for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency.
